Warburg Research Analysts Give Fresenius SE & Co KGaA (FRE) a €80.00 Price Target

Fresenius SE & Co KGaA (FRA:FRE) received a €80.00 ($95.24) target price from research analysts at Warburg Research in a report released on Wednesday, December 27th. The firm currently has a “buy” rating on the stock. Warburg Research’s price target suggests a potential upside of 22.03% from the stock’s current price.

A number of other equities research analysts have also recently weighed in on the stock. Commerzbank set a €85.00 ($101.19) price objective on shares of Fresenius SE & Co KGaA and gave the stock a “buy” rating in a report on Monday, November 6th. Kepler Capital Markets set a €63.00 ($75.00) price objective on shares of Fresenius SE & Co KGaA and gave the stock a “neutral” rating in a report on Tuesday, November 28th. HSBC set a €70.00 ($83.33) price objective on shares of Fresenius SE & Co KGaA and gave the stock a “neutral” rating in a report on Wednesday, November 22nd. Deutsche Bank set a €83.00 ($98.81) price objective on shares of Fresenius SE & Co KGaA and gave the stock a “buy” rating in a report on Friday, December 1st. Finally, Bank of America set a €75.00 ($89.29) price objective on shares of Fresenius SE & Co KGaA and gave the stock a “neutral” rating in a report on Monday, November 6th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and eleven have issued a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of €78.66 ($93.65).

Shares of Fresenius SE & Co KGaA (FRA FRE) traded up €0.40 ($0.48) on Wednesday, reaching €65.56 ($78.05). 4,174 shares of the company’s stock were exchanged. The stock has a market capitalization of $36,290.00 and a PE ratio of 20.88. Fresenius SE & Co KGaA has a twelve month low of €60.16 ($71.62) and a twelve month high of €80.00 ($95.24).

TRADEMARK VIOLATION NOTICE: “Warburg Research Analysts Give Fresenius SE & Co KGaA (FRE) a €80.00 Price Target” was first published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this piece of content on another domain, it was illegally copied and reposted in violation of U.S. and international copyright & trademark legislation. The correct version of this piece of content can be viewed at https://ledgergazette.com/2018/01/13/fresenius-se-80-00-by-warburg-research.html.

Fresenius SE & Co KGaA Company Profile

Fresenius SE & Co KGaA, a health care group, provides products and services for dialysis, hospitals, and outpatient medical care worldwide. The company operates through Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed segments. The Fresenius Medical Care segment offers products for patients with chronic kidney failure.

Analyst Recommendations for Fresenius SE & Co KGaA (FRA:FRE)

Receive News & Ratings for Fresenius SE & Co KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius SE & Co KGaA and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply